FibroBiologics, Inc. FBLG 深 滬
等待開盤 06-25 09:30:00 美东时间
0.7694
+0.019
+2.55%
華盛通- 最 高0.7833
- 今 開0.7503
- 成交量 15.17万股
- 最 低 0.7503
- 昨 收 0.7503
- 總市值 400.77万
- 52周最高 14.678
- 市盈率 靜 --
- 換手率 2.91%
- 52周最低 0.745
- 委 比 -77.78%
- 總股本 520.89万
- 歷史最高 1100.00
- 量 比 0.91
- 振 幅 4.40%
- 歷史最低 0.7503
- 每 手 1
- 風險率 4.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.
06-03 18:46
FibroBiologics Files New Provisional Patent Application With USPTO Titled 'Oral Fibroblasts And Fibroblast-Derived Therapeutics And Delivery Systems For Same'
The application covers oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.The provisional patent application describes an
05-18 20:34
FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target Hantavirus
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using
05-11 20:32
Maxim Group Downgrades FibroBiologics to Hold
Maxim Group analyst Michael Okunewitch downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
05-04 20:54
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interim data expected in Q3 2026.
05-04 20:16
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
FBS Global Receives Non-Compliance Notice From Nasdaq
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the NoticeSINGAPORE, April 16, 2026 (GLOBE NEWSWIRE) -- FBS Global Limited
04-16 19:47
FibroBiologics Receives European Patent Titled 'De-Differentiated Fibroblast-conditioned Media For Treating Or Preventing Disc Degeneration'
https://x.com/PatentGrants/status/2044505323562783041?s=20
04-16 03:59
D. Boral Capital Downgrades FibroBiologics to Hold
D. Boral Capital analyst Jason Kolbert downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
03-27 02:30
